2025/09/02 by Sunish Shah, Sahil Angelo, Brandon Smith +1 · 1 voice
Biochemistry, Genetics and Molecular Biology · Medicine · Immunology and Microbiology · #Antibiotic Resistance in Bacteria #Antibiotics Pharmacokinetics and Efficacy #Antibiotic Use and Resistance
paper · doi:10.1080/14656566.2025.2558990
openalex publication_date 2025/09/02 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/16
INTRODUCTION: Enmetazobactam, taniborbactam, and zidebactam are novel β-lactamase inhibitors that have been combined with cefepime in an effort to overcome common and emerging mechanisms of antimicrobial resistance. AREAS COVERED: , animal, and clinical data for cefepime-enmetazobactam, cefepime-taniborbactam, and cefepime-zidebactam to forecast their potential role in clinical practice. EXPERT OPINION: activity of cefepime-zidebactam fills critical gaps for the most challenging Gram-negative pathogens, including those that harbor metallo-β-lactamases with or without mutations in penicillin-binding proteins. For each of these agents, clinical data and real-world evidence generation are needed to better define their therapeutic niche, potential for resistance selection, and potential benefits compared to currently available antibiotics.